{"id":"NCT02265705","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10","primaryCompletion":"2017-05","completion":"2017-05","firstPosted":"2014-10-16","resultsPosted":"2019-03-13","lastUpdate":"2019-09-11"},"enrollment":290,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Baricitinib","otherNames":["LY3009104","INCB 028050"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Baricitinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as baricitinib in participants with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy.","primaryOutcome":{"measure":"Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20)","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo","deltaMin":28.3,"sd":null},{"arm":"Baricitinib","deltaMin":58.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":21},"locations":{"siteCount":30,"countries":["Argentina","Brazil","China"]},"refs":{"pmids":["34706874","33959198","33237533","32876903"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":145},"commonTop":["Upper respiratory tract infection","Hyperlipidaemia","Urinary tract infection","Nasopharyngitis","Hypertension"]}}